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Sarcomas are divided into a group with speciﬁc alterations and a second presenting a complex karyotype, sometimes diﬃcult to
diagnose or with few therapeutic options available. We assessed if miRNA proﬁling by TaqMan low density arrays could predict
the response of undiﬀerentiated rhabdomyosarcoma (RMS) and osteosarcoma to treatment. We showed that miRNA signatures
in response to a therapeutic agent (chemotherapy or the mTOR inhibitor RAD-001) were cell and drug speciﬁc on cell lines and a
rat osteosarcoma model. This miRNA signature was related to cell or tumour sensitivity to this treatment and might be not due to
chromosomal aberrations, as revealed by a CGH array analysis of rat tumours. Strikingly, miRNA proﬁling gave promising results
for patient rhabdomyosarcoma, discriminating all types of RMS: (Pax+) or undiﬀerentiated alveolar RMS as well as embryonal
RMS. As highlighted by these results, miRNA proﬁling emerges as a potent molecular diagnostic tool for complex karyotype
sarcomas.
1.Introduction
Sarcomas are rare malignant tumours arising in connec-
tive tissues like fat, muscle, bones, and cartilage. Accord-
ing to molecular cytogenetic alterations, sarcomas could
be divided into two classes: (1) sarcomas with speciﬁc
alterations (translocation, oncogenic mutation) including
Ewing sarcoma, gastrointestinal stromal tumours, and alve-
olar rhabdomyosarcoma (2) sarcomas with complex kary-
otype like leiomyosarcoma, pleomorphic liposarcoma, or
osteosarcoma. Osteosarcoma is the most frequent primary
malignant bone tumours, characterized by its metastatic
potent particularly in lung sites and its resistance to con-
ventional treatments like chemotherapy and radiotherapy
[1]. Even if the median survival of osteosarcoma patients
has been improved through preoperative administration of
chemotherapeutic agents, there are nowadays around 40%
poor-responder patients [2]. In fact, osteosarcoma tumours
often resist or relapse to presurgical chemotherapeutic
treatment, and only few therapeutic options are possible
and generally noncurative [3]. A second intensive cure of
chemotherapy is currently administered in this case. Thus, it
seems essential to develop a diagnosis tool to predict tumour
response to chemotherapy to avoid the administration of
ineﬃcient drugs. There is also a need for eﬃcient therapeutic
alternatives based on the discovery of new targets involved in
osteosarcoma tumourigenesis.
Rhabdomyosarcoma (RMS) is one of the most common
soft-tissue sarcoma. Three types of RMS are observed:
alveolar RMS (20%), embryonal RMS (eRMS, 60%), and
pleomorphic RMS (20%). 70% aRMS present a speciﬁc
translocation of the transcription factor Pax3 at the 3 end
of FOXO1, creating a potent transcription factor able to
induce myogenesis and survival [4]. 10% aRMS present2 Sarcoma
a translocation of Pax7 with FOXO1 [5]. aRMS are of bad
prognosisascomparedtoeRMS,particularlythosewithPax3
fusion gene [6]. Thus, it appears primordial to obtain a
diagnosis tool identifying precisely the RMS subtypes, and
particularly discriminating Pax-aRMS from eRMS, diﬃcult
to separate according to patient survival characteristics, gene
expression proﬁles, and CGH arrays [7].
Micro-RNAs (miRNAs) are promising diagnosis bio-
markers with their tissue speciﬁcities and their involve-ment
in oncogenic process [8]. miRNAs are non-coding small
RNA molecules synthesized from intronic regions with a
size range from 16 to 35 nucleotides. They are processed by
speciﬁc complexes of proteins containing Drosha and Dicer
to be matured and ﬁnally integrated in RISC complexes
[9, 10]. Mature miRNAs match with complementary
sequences in messenger RNAs resulting in translation
inhibition and accelerated mRNA degradation [11]. miRNA
expression levels are characteristic for one tissue to regulate
gene expression during growth and development, as it
was shown for skeletal tissue and muscle development
[12–14]. Their expression is also deregulated in many
cancers [15, 16], resulting in a tumour miRNA signature,
which could be useful for their classiﬁcation in line with
their tissue origin and molecular alterations [17–19]. Thus,
they currently constitute potent biomarkers for cancer diag-
nosis [18, 20] with their abilities to be detected in patient
serum. A noninvasive diagnostic tool based on miRNAs for
osteosarcoma could be very useful to adapt chemotherapy
protocols to tumour biological speciﬁcities.
In this study, we performed the miRNA proﬁling of sar-
coma cell lines, human or rat tumours, to assess if miRNAs
could constitute potent biomarkers to surpass the current
limitations for rhabdomyosarcoma diagnosis and osteosar-
coma treatment. miRNA expression levels were determined
using microﬂuidic cards performing high-throughput Taq-
Man Low Density Arrays (TLDA), a real-time quantitative
PCR (RT-qPCR) assays based on TaqMan technology. We
ﬁrstly studied the eﬀects of diﬀerent chemotherapeutic
agents on osteosarcoma cell miRNA proﬁles; we observed
that these miRNA signatures were cell speciﬁc and drug spe-
ciﬁc. A CGH array of osteosarcoma tumours obtained from
a rat model revealed that this miRNA signature, conserved
in rat and human cells, was independent of chromosomal
rearrangements, suggesting that miRNA proﬁles were linked
to tumour phenotypes rather than to their genetic back-
ground. Of great interest, a miRNA signature was identiﬁed
in rhabdomyosarcoma tumours from patients in accordance
with the molecular translocation Pax3 or Pax7. This sig-
nature was in fact a potent tool to discriminate alveolar
RMS (Pax-) from embryonal RMS, indistinguishable by the
molecular techniques currently used. In conclusion, miRNA
proﬁling constitutes a promising technology as an alternative
or a partner of usual molecular techniques to overcome the
present diﬃculties in diagnosis and treatment of sarcomas.
2.ExperimentalProcedures
2.1. Human Rhabdomyosarcoma Tumours. Seventeen pa-
tients treated for rhabdomyosarcoma in the Centre L´ eon
B´ erard were included in this study. Four frozen tumours and
thirteen formalin-ﬁxed paraﬃn-embedded tumours were
obtained from biopsies realized at the diagnosis. Tumour
diagnoses were realized by a referent anatomopathologist
specialist for this pathology by immunohistochemistry,
FISH, and qPCR.
2.2. Cancer Cell Lines. Five cancer cell lines were obtained
from ATCC (Manassas, VA, USA): the two human osteosar-
coma MNNG/HOS Cl #5 [R-1059-D] (reference CRL-15-
47) and Saos-2 (HTB-85) cells, the chondrosarcoma cell line
SW1353 (HTB-94) and the two Burkitt lymphoma Daudi
(CCL-213) and Namalwa (CRL-1432) cells. Osteosarcoma
and chondrosarcoma cells were grown in DMEM (Gibco,
Carlsbad, CA, USA), supplemented with 10% decomple-
mented fetal calf serum (Lonza, Basel, Switzerland), 10mL
penicillin streptomycin (10U/mL/10μg/mL, Gibco, Carls-
bad, CA, USA), and 5mL L-glutamin (200mM; Gibco)
at 37◦C humidiﬁed atmosphere containing 5% CO2.L y m -
phoma cells were grown in RPMI (Gibco, Carlsbad, CA,
USA). Cells were exposed to 100nM RAD-001 (Novartis),
50μM ifosfamide (ifos, Baxter) or 1μM cisplatin (CDDP,
TEVA)or100μMmethotrexate(MTX,TEVA)for24,48,and
72h.
2.3. Rat Osteosarcoma Model. Procedures for animal care
were performed according to institutional and national
guidelines. Animals were anesthetized throughout all
surgical and imaging procedures with isoﬂurane/oxygen
(2.5%/2.5%, v/v) (Minerve, Esternay, France). The trans-
plantable orthotopic and metastatic rat osteosarcoma model
has been previously described [21–23]. This model mim-
ics its human counterpart in terms of aggressiveness,
metastatic spreading and chemoresistance phenotype [21–
23]. All the tumours obtained were classiﬁed as osteoblastic
following histological analyses. Brieﬂy, small tumour frag-
ments (100mm3) taken from a hyperproliferative osteogenic
tumour area were grafted on 3-weeks old immunocom-
petents Sprague-Dawley rats (Charles River Laboratories,
Wilmington, MA, USA). Using a lateral approach, a tumour
fragment was placed contiguous to tibial diaphysis after
periosteal abrasion; then, the cutaneous and muscular
wounds were sutured. Fourteen days after tumour trans-
plantation, animals underwent a ﬁrst 18F−FDG PET Scan
and were randomly assigned to a control group treated with
saline solution or a treated group exposed to a subcutaneous
dose of 10mg/kg ifosfamide (ifos, Baxter, Deerﬁeld, IL,
USA),7daysapart(atdays15and22aftertumourtransplan-
tation). A second 18F−FDG PET Scan was performed 7 days
after the second ifos administration. Animals were sacriﬁced
one week after the end of the treatment. Tumour and normal
tissue fragments (muscle, bone, and lung) were collected for
RNA extractions.
2.4. RNA Extraction and Quantitative Real-Time PCR. FFPE
tumours were lysed for 24h in ATL buﬀer (Qiagen, France)
supplemented with proteinase K (Qiagen) at 60◦Ci nr o t a t i v e
agitation after diﬀerent washes with toluene, ethanol, andSarcoma 3
tris/EDTA in this order. Total RNA was extracted from
tumour or cell pellets using a single phenol/chloroform
extraction protocol with Trizol, according to the manufac-
turer’s instructions (Invitrogen, Carlsbad, CA, USA). Five
hundred nanograms of total RNA were subjected to the
microﬂuidic PCR technology performed by Applied Biosys-
tems (Foster City, CA, USA). In brief, RNA was reversed
transcribed, using multiplexed speciﬁc looped miRNA
primers from the Taqman MicroRNA Reverse Transcription
kit. The second step consists in a real-time quantitative PCR
on TLDA: RT products are introduced through microchan-
nels into miniature wells that are preloaded with dehydrated
speciﬁc primers and probes. Recently, Applied biosystems
released the second version of TLDA, consisting of two cards
A and B. Analyses were performed for 377 miRNAs on card
A and 290 on card B.
2.5. PCR Data Normalization. For each miRNA, the thresh-
old cycle (Ct) was calculated by the ABI 7900 Sequence
Detection System software (plate by plate manual Ct analysis
with a threshold at 0.25 and automatic baseline). All further
data manipulations were done using R scripts. A cutoﬀ
of 32 was applied to discard the late Ct values, except
for RMS analysis. Around 60% of miRNAs passed the
ﬁltering criteria and were used for further analysis. For
each TLDA, quality controls were performed on the raw
data by checking internal controls and using box plot and
scatter plot diagrams. Samples with any kind of problems
were discarded so they would not introduce bias during
the following normalization procedures. We tested diﬀerent
methods of normalization since the recommended “pseudo”
normalization factor mammU6 plotted in each card was
not stably expressed in our diﬀerent samples. Normalization
with the two most stable miRNAs identiﬁed by GeNorm
was not optimal too. Finally, a global normalization by
the median was chosen for its reliability over experiments.
Tissues included in a given analysis were treated altogether,
the normalization procedure being applied separately for
the two types of card, A and B. Distribution of normalized
data was checked with box plots and correlation plots. The
followingformulawasusedtocorrectCtvaluesofeverycard:
(Normalized Ct) =
Ct ×(mean of medians)
(median of the card)
. (1)
Through this approach, the new median value shared by
all samples can be considered as a sort of perfect “virtual
housekeeping gene”. Therefore, the standard ΔΔCt method
can be used to determine the relative quantities (RQ) as
follows:
ΔCt = (Normalized Ct) −(New shared median). (2)
For the ΔΔCt calculation, it was more relevant for the
statistical analyses to use the mean of all ΔCt obtained across
samples for each miRNA, instead of using the ΔCt of a
reference sample
ΔΔCt
= ΔCt −

Mean of ΔCt across samples for each miRNA

,
(3)
RQ = 2
−(ΔΔCt) (4)
2.6. miRNA Target Predictions. We compiled 4 databases
to determine miRNA targets: TargetScan 5.1, MiRanda,
PICTAR, and the miRbase databases. These databases search
the presence of conserved 8mer and 7mer sites on the 3 UTR
parts of messenger RNA that match the seed region of each
miRNA. It also predicts the eﬃcacy of targeting for each
matchingsite.Wecreatedourowndatabasewhichregrouped
each miRNA with the geneID of all their protein targets, for
rat and human. We only conserved couples miRNA/geneID
present in two databases at least.
2.7. miRNA-Regulated Cell Signalling Pathways Predictions.
We used the “G-language microarray” web application,
which allows the mapping of molecular dataset onto “Kyoto
Encyclopedia of Genes and Genomes” (KEGG) pathway
maps [24]. We ﬁrst input miRNA-targeted proteins of
interest and the sum of RQ values for all miRNAs that
regulate these proteins, contained between 1 and 50; the
softwarethengeneratesKEGGdatatocreateFLASHgraphics
of cell signalling pathways in which proteins are involved.
The colour intensity of a highlighted protein varies with the
strength of its regulation by miRNAs.
2.8. Proliferation Assay. Cells were plated in 96 well plates
at 5000cells/well and exposed to 100nM RAD-001, 50μM
ifosfamide, 100μM methotrexate, or 1μM cisplatin or not
(NT). Cell growth was measured 24, 48, and 72h later
with 20μL Cell Titer Glo luminescent reagent (Promega,
Madison, WI, USA) for 10min. Luminescence was recorded
using a Microbeta reader (PerkinElmer, Fremont, CA, USA).
2.9. Western Blot. Pelleted cells were resuspended in lysis
buﬀer (Tris 50mM pH 7.4, NaCl 250mM, EDTA 5mM,
NaF 50mM, Triton X-100 0.1%, orthovanadate 1μM) plus
proteaseinhibitorsfor30minonice.Afteracentrifugationat
14000rpm for 10min, supernatants were boiled for 5min in
Laemmli sample buﬀer (Biorad, Hercules, CA, USA). Analy-
sis of protein content was performed on 4%–12% gradient
gel. After electrophoretic separation, 30μg proteins were
electrotransferred on a polyvinylidene diﬂuoride membrane
(Immobilon P, Millipore corp., Bedford, MA, USA). The
membrane was then blocked for 1h at room temperature
with blocking agent 0.2% in PBS/Tween 0.1%, probed
overnight with a primary rabbit antibody against the protein
of interest, and ﬁnally revealed with a secondary antirabbit
antibody HRP conjugated (Upstate Biotechnology, Lake
Placid, NY, USA) and ECL Advance system (GEhealthcare,
Chicago, IL, USA). Primary antibody used was obtained
from Cell Signaling (New England Biolabs, Beverly, MA,4 Sarcoma
USA) used at 1/1000. The β actin was used as a reference
(Sigma).
2.10. CGH Array. Oligonucleotide-based microarray analy-
sis was performed using a custom-designed, 244K-feature
whole-rat genome microarray manufactured by Agilent
Technologies (Santa Clara, CA). Genomic DNA labeling,
array hybridization, and washing were performed as spec-
iﬁed by the manufacturer (Agilent Technologies). Results
of aberration calls consisting of three or more consecutive
oligos were then displayed using custom oligonucleotide
CGH analysis software (Genespring).
2.11. Statistical Analysis. Normalized RQ data were directly
input into the TIBCO Spotﬁre DecisionSite for Functional
Genomics analysis software. We performed unsupervised
hierarchical clustering to classify samples by groups. The
selection of miRNAs useful to predict tumour response to
treatment was statistically realized using ANOVA tests with P
valuesof.05atleast.Resultswereveriﬁedthroughsupervised
hierarchical clustering.
Data from miRNA lists of interest were then used as vari-
ables in a three-dimensional principal component analysis
(PCA) performed with R 2.9.0 package to demonstrate their
capabilities to distinguish types of tumours. PCA supplies
a simpliﬁed three-dimensional picture to our multivariate
dataset of miRNA RQ values. By mathematical combina-
tion of values according to their strength, three principal
components are created that represent as much as possible
the variability of the data. Thus, tumours possess three new
coordinates in a three-dimensional space. According to their
localization in this space, tumours form groups, and their
subtypes can be predicted.
3. Results
3.1. miRNA Signatures of Osteosarcoma Cell Lines. In our
recent study published in International Journal of Cancer,
we showed that the two osteosarcoma Saos-2 and CRL-15-
47 (15-47) cells mimic the biological response of human
osteosarcoma and tumours obtained from a rat model. In
fact, we identiﬁed in an osteosarcoma rat model a panel of
61 miRNAs discriminating tumours with a good response
to ifosfamide from those with a bad response [25]. On the
basis of this signature, we realized a principal component
analysis allowing predicting tumour response. In this PCA
diagram, we could notice that the Saos-2 cells were predicted
as sensitive to ifosfamide contrary to 15-47 cells (Figure 3(b)
[25]), according the results obtained by a proliferation assay
(Figure 6(a) [25] and Figure S1). This was conﬁrmed by a
PCA analysis realized with the miRNA signature identiﬁed in
humantumours(FigureS2).Wesoconsideredthatthesetwo
cell lines were an interesting model to study the importance
of miRNAs in cell response to treatment and to identify new
therapeutic strategies.
3.2. miRNA Signatures of Human Cancer Cell Lines. We
ﬁrstlyperformedapreliminary miRNAproﬁling ondiﬀerent
cell models to compare the miRNA proﬁles of osteosarcoma
cells used in our laboratory to perform in vitro experiments,
Saos-2 and 15-47 cells, with the chondrosarcoma cells SW-
1353 (chondro) and the Burkitt lymphoma Daudi and
N a m a l w ac e l l s .I nap r e v i o u ss t u d y ,w ei d e n t i ﬁ e d6 1m i R N A s
involved in osteosarcoma cell response to treatment [25].
We only conserved these miRNAs to realize an unsupervised
hierarchical clustering with the ﬁve cancer cell lines. As
shown in Figure 1(a), this miRNA signature was represen-
tative of the two human osteosarcoma cell lines, since these
two cells clustered together independently but closely to the
chondrosarcoma cells. These three cell lines were classed in
a distinct group from the two lymphoma cells Daudi and
Namalwa. This conﬁrmed that each cancer cell line presents
a miRNA signature in accordance with their origin, as shown
by others [15, 16].
3.3. miRNA Proﬁles in Response to Chemotherapeutic Agents
Were Cell Speciﬁc. Then, we assessed if miRNA proﬁles were
speciﬁcally modiﬁed in response to chemotherapy. We chose
to expose osteosarcoma and lymphoma cells to ifosfamide,
an alkylating chemotherapeutic agent currently used for
paediatric osteosarcoma. A proliferation assay based on ATP
measurement showed that the only Saos-2 cell line was
moderately sensitive to 50μMi f o s f a m i d ea f t e r4 8he x p o s u r e
(proliferation inhibition around 30%) (Figure S1). Based
on this observation, we decided to expose these cells to
50μM ifosfamide for 24h to realize miRNA proﬁling. On the
basis of the panel of 61 miRNAs identiﬁed in our previous
study [25], osteosarcoma cells were markedly diﬀerent from
lymphoma cells, conﬁrming that miRNA proﬁles were cell
speciﬁc as shown by the unsupervised hierarchical clustering
in Figure 1(b). We could notice that Saos-2 cells present a
unique miRNA signature in which the majority of miRNAs
were overexpressed (in red in Figure 1(b)). A supervised
hierarchical clustering realized following an ANOVA P<
.03 between the Saos-2 sensitive cells versus the resistant
cells revealed that they eﬀectively clustered according to
their sensitivity to ifos: Saos-2 in one hand, independently
to 15-47 cells and both lymphoma cells (Figure 1(c)). We
conﬁrmed this observation with the other chemotherapeutic
agentciplatin.Aspreviously,cellswereclassiﬁedaccordingto
their susceptibility to CDDP on the supervised hierarchical
clustering in Figure S3A (ANOVA P<. 03): the 15-47 and
Namalwa cells, sensitive to CDDP based on the proliferation
assay in Figure S3B, clustered together, independently to
Daudi and Saos-2 cells refractory to this treatment.
3.4. Osteosarcoma Cell miRNA Proﬁles Were Speciﬁc of Each
Chemotherapeutic Agent. Thus, since miRNA signatures of
u n t r e a t e da sw e l la st r e a t e dc e l l sw e r ec a n c e rs p e c i ﬁ c ,w e
assessed if each chemotherapeutic drug induced a diﬀerent
miRNA proﬁle in a same cell. As suggested previously
for osteosarcoma cells, cisplatin and ifosfamide exposure
resulted in quite diﬀerent miRNA proﬁles. After a statistical
analysis with an ANOVA P<. 03, we only found two
dicriminating miRNAs common to both miRNA signatures
induced by ifos and CDDP in the two cell lines (Figure S3).
In this context, we test a third cytotoxic agent currently
administered in osteosarcoma pathology, the methotrexate.Sarcoma 5
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Figure 1:CancercellmiRNAsignatureswereconsistentwiththeirtissueoriginandwiththeirsensitivitytoifosfamide.(a)Thisunsupervised
hierarchical clustering only conserved the 61 miRNAs which discrimated osteosarcoma cells according to their response to treatment.
Osteosarcoma cell lines clustered together near chondrosarcoma cells and independently to the lymphoma Daudi and Namalwa cells. Each
row represents the relative levels of expression for each miRNA, and each column shows the expression levels for each sample. The red or
green colour indicates relatively high or low expression, respectively, while grey squares indicate no expressed miRNA. (b) and (c) miRNA
proﬁles after exposure to 50μM ifosfamide for 24h. (b) This unsupervised hierarchical clustering only conserved the 61 miRNA diﬀerently
expressedinosteosarcomacellsaccordingtotheirsensitivitytoifosfollowinganANOVA(P<. 03).(c)Thissupervisedhierarchicalclustering
conserved miRNAs diﬀerently expressed in cells according to their response to treatment following an ANOVA (P<. 05) after removing the
miRNAs whose expression depends on the cell types. The red or green colour indicates relatively high or low expression, respectively, while
grey squares indicate no expressed miRNA.
As shown in the unsupervised hierarchical clustering in
Figure 2, only conserving the 61 miRNAs of interest for
osteosarcoma response, as explained above, the miRNA
signature in the two osteosarcoma cells Saos-2 and 15-47
strongly diﬀered from those observed for ifsofamide and
cisplatin. It is important to note that a majority of these
miRNAs were overexpressed in both cell lines in response
to MTX. This was relevant with their sensitivity to MTX
as shown in the proliferation assay in Figure 2(b).I n
brief, it seems that discriminating miRNAs were generally
overexpressed in the cells after exposure to a cytotoxic
agent, to which they were sensitive, as it was also shown
for ifosfamide in the Saos-2 cells (Figure 1(b)). This also
conﬁrmed that miRNAs predicting cell response to a
treatment diﬀered according to the drug.
Onthebasisofthesepreliminaryinvitroresults,wecould
suggest that miRNA proﬁles, due to their drug speciﬁcity,
could be a potent tool to predict a cancer cell response
to a treatment. Since osteosarcoma is currently resistant to
conventionaltreatments,thepredictionofitsresponsetoone
agent could be a progress for this pathology.
3.5. Osteo- and Chondrosarcoma Cell Response to the mTOR
Inhibitor RAD-001. As highlighted by these previous data,
we were able to classify and predict osteosarcoma cell
response to chemotherapy. Our algorithms were not only
interesting for chemotherapeutic agents but also promising
toidentify newtargetedtherapies toencounterosteosarcoma
resistance. Thus, we tested a potent drug for skeletal sarcoma
treatment, which inhibits the pro-oncogenic protein
mTOR, called RAD-001 (Everolimus, Novartis). mTOR
is often aberrantly activated in cancers and, in particular
in chondrosarcoma [26] and osteosarcoma [27]. mTOR
signalling has been described as implicated in tumour
development, metastasis, and drug resistance [28, 29];
thus, mTOR targeting successfully inhibits tumour growth
and renders them sensitive to conventional treatments
[30, 31]. RAD-001, acting in a similar manner than
rapamycin through the inhibition of mTORC1 complexes,
is currently tested in various clinical trials for renal cell
carcinoma (RECORD program), advanced papillary
tumours (RAPTOR), metastatic neuroendocrine tumours
(RAMSETE), or breast cancers (BOLERO).
Thus, we performed in vitro experiments on chon-
drosarcoma and osteosarcoma cells with 100nM RAD-
001. The Saos-2 and chondrosarcoma cell proliferation was
reduced of 40% following exposure to RAD-001 during 72h
contrary to 15-47 cell growth (Figure 3(a)). In parallel, we6 Sarcoma
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Figure 2: miRNA expression proﬁles osteosarcoma cells were
speciﬁc for each chemotherapeutic agent. (a) This unsupervised
hierarchical clustering conserved the miRNAs identiﬁed as dis-
criminating for ifosfamide response after removing the miRNAs
whose expression depends on the cell types. Each row represents
the relative levels of expression for each miRNA, and each column
shows the expression levels for each sample. The red or green
colourindicatesrelativelyhighorlowexpression,respectively,while
grey squares indicate no expressed miRNA. (b) Cell growth was
measured by the Cell Titer GloLuminescent assay as described in
Section 2.6 24, 48, and 72h after exposure to 100μM methotrexate.
Results were represented as the mean % of proliferation normalized
to untreated cells of two independent experiments realized in
duplicate.
realized Western blot with RAD-001 on chondrosarcoma
and osteosarcoma cells concerning the major actors of the
mTORcellsignallingpathways.ThisrevealedthatthemTOR
pathway was inhibited by RAD-001 in chondrosarcoma cells
contraryto15-47cells,inparticulareIF4Gandp70S6kinase
whose phosphorylation level was decreased (Figure 3(b)).
Thus, we analysed if the miRNA signatures of these cells
were diﬀerent and couldexplain their diﬀerential response to
RAD-001. We performed a supervised hierarchical clustering
between untreated Saos-2, chondrosarcoma and 15-47 cells
following an ANOVA with P<. 05. This clustering revealed
that 16 miRNAs discriminated the chondrosarcoma and
Saos-2 cells in one hand and the 15-47 cells in the other hand
(Figure 4). Except miR-146, Saos-2 and chondrosarcoma
overexpressed these contributory miRNAs.
The r eaft e r ,asw eha v ee x p lai n edi no urp r evi o usst ud yo n
osteosarcoma[25],miRNAproﬁlingconstitutesapotenttool
to identify miRNA-targeted cell signaling pathways through
an in silico approach. In our case, we searched if these miR-
NAs shown as diﬀerently expressed in cells according to their
response to RAD-001 potentially target the mTOR signalling
pathway. We created a database, as described in Section 2.6
which determine the predicted targets for these miRNAs
described in the miRbase. Then, we summed up the RQ
values for each miRNA in the Saos-2 and chondrosarcoma
cells sensitive to RAD-001 and concatenated with the geneID
of their protein targets. We ﬁnally inserted these data in
the G-language microarray web application, which connects
miRNA targets according to their involvement in similar
KEGG pathways, the mTOR pathway in this case. As shown
in Figure 5, the mTOR pathway is targeted by these miRNAs
andparticularlyitsdownstreamproteinsimplicatedinVEGF
signaling and autophagy processes, in particular RICTOR,
ATG1, and HIF-1a. Thus, the Saos-2 and chondrosarcoma
cells overexpressed miRNAs that potentially inhibit mTOR
signalling. Inhibition of these miRNAs through the use of
Locked Nucleic Acid (LNA) and qPCR measurement of
RICTOR, ATG1, and HIF1a could conﬁrm this concept.
To resume, miRNAs constitute potent biomarkers to
determine the susceptibility to a treatment and could be very
useful to identify new therapeutic targets as an alternative of
chemotherapy for chondrosarcoma and osteosarcoma often
refractory to this treatment. In the next steps, we assessed if
these observations were relevant in vivo,w i t ham o d e lo fr a t
osteosarcoma and with patient samples.
3.6. Predictive miRNA Signature of a Rat Osteosarcoma Model
Was Probably Not Related to DNA Aberrations. As described
inotherstudiesrealizedbymembersofourteam[21,22,25],
we possess a rat osteosarcoma model mimicking the human
pathology concerning aggressiveness, chemoresistance and
the apparition of lung metastases (see Section 2.6). The
treatment of animals with ifosfamide results in two groups,
the good versus the bad or moderate responders, in a
proportion closer to that observed for patients. By miRNA
proﬁling, we were able to distinguish tumours sensitive to
ifosfamide from those refractory to this drug and above
all to predict the response of untreated tumours with ten
miRNAs through the use of statistical algorithms created
in our lab [25]. Following these interesting data, we would
like to conﬁrm that this miRNA signature was speciﬁc of
tumour response to treatment and not related to diﬀerent
tumour genetic backgrounds. We thus realized an analysis
in CGH array with the same tumours used for miRNA
proﬁling. We analysed two tumours of each type, untreated,
treated with ifosfamide and good responder, or treated
with ifosfamide and bad responder, as compared to theSarcoma 7
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Figure 3: mTOR inhibition by RAD-001 in chondrosarcoma resulted in cell proliferation inhibition. (a) Cell growth was measured by the
Cell Titer GloLuminescent assay as described in Section 2.6 24, 48, and 72h after exposure to 100nM RAD-001. Results were represented as
the mean % of proliferation normalized to untreated cells of two independent experiments realized in duplicate. A Fisher test was realized,
NS corresponds to “nonsigniﬁcant”. (b) Western blot analysis of RAD-001 eﬀects on the mTOR pathway in the chondrosarcoma and 15-47
osteosarcoma cells exposed or not (NT) to doxorubicin (dox). 30μg protein extracts were analysed by Western blot with antibodies 1/1000
against actors of the mTOR pathway (phosphorylated form or not) (Cell signalling, Beverly MA).
same untreated bone sample, the reference tissue in CGH
analysis. The majority of chromosomal aberrations observed
inCGHarraywascommontountreatedtumoursandtreated
tumours,regardlessoftheirresponsetotreatment(Figure 6).
The few diﬀerent abnormalities were essentially linked to
individual tumour biological speciﬁcities.
We compiled all abnormalities and veriﬁed in our
“home-made” database if any miRNA, identiﬁed as discri-
minating of tumour response, was located in these DNA
regions. Interestingly, this in silico analysis also revealed that
neither miRNA nor gene were present in the few diﬀerential
aberrations observed in these tumours, in particular in the
chromosome 4 (Figure S4), suggesting that the diﬀerent
miRNA proﬁles were rather linked to tumour response to
treatment and not due to upstream chromosomal rearrange-
ments. Although we could not rule out that some trans-
acting proteins could be deregulated consequently to these
aberrations, this suggested that all tumours were homo-
geneous and that an increase in some miRNAs in sensitive
tumours were due to their upregulation and not to a genetic
ampliﬁcation.
It seems that molecular diagnosis based on miRNA pro-
ﬁling highlights the tumour behaviour, that is, in response to
a treatment, and thus a phenotype rather than a genotype
contrary to CGH array. These two molecular techniques
could be a couple of choice to improve the care of patients
with pathologies currently hardly to diagnose.
3.7. Rhabdomyosarcoma miRNA Proﬁles Were Correlated to
their Histological Subtypes. Finally, to corroborate the pre-
vious idea considering that miRNA proﬁling could be very
helpful for uncertain diagnoses, we performed the miRNA
proﬁling of rhabdomyosarcoma samples. In fact, we recently
showed that miRNA proﬁling was reliable for osteosarcoma
diagnosis on 29 formalin-ﬁxed paraﬃn embedded (FFPE)
biopsies of patients [25]. Based on the expression level of
a panel of ﬁve miRNAs, we successfully separated good
responders from bad responders to treatment. So, we
assessed if our TLDA platform was also competitive for
RMS diagnosis. We obtained seventeen tumours including
alveolar RMS patients, (Pax3+) (3 patients) or Pax7+ (2),
embryonal RMS patients (6) and negative fusion aRMS (6).8 Sarcoma
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Figure 4: miRNA expression proﬁles of osteosarcoma and chon-
drosarcoma cells were consistent with their sensitivity to the
mTOR inhibitor RAD-001. This hierarchical clustering only con-
served miRNA diﬀerently expressed in tumours according to their
response to treatment following an ANOVA (P<. 05). Each row
represents the relative levels of expression for each miRNA and each
column shows the expression levels for each sample. The red or
greencolourindicatesrelativelyhighorlowexpression,respectively,
while grey squares indicate no expressed miRNA.
All these tumours were diagnosed through the use of
immunohistochemistry, FISH and qPCR, which were val-
idated by a referent anatomopathologist (Table S5). A
supervised hierarchical clustering on rhabdomyosarcoma
tumours following an ANOVA with a P value <. 03 between
the four types of RMS, revealed that tumours clustered
according to their molecular alterations Pax3/FOXO1, Pax7/
FOXO1 or no translocation, on the basis of the expres-
sion level of 10 miRNAs (Figure 7(a)). (Pax+) tumours,
particularly those (Pax3+) overexpressed all these miRNAs.
Then, we performed a statistical analysis with these ten
miRNAs based on Principal Component Analysis, a method
which allows studying the variability between a set of
variables. This consists of assigning a new system of three
coordinates to each contributory miRNA by a mathematical
procedure. Then, RQ values of each miRNA are adjusted
for each tumour by the new coeﬃcients obtained previously
and summed up. Thus, a 3-dimension PCA diagram was
realized with the three new coordinates for each tumour
(Figure 7(b)). Through this mathematical representation,
we could distinguish (Pax+) from fusion negative aRMS
and eRMS. eRMS also constitutes an independent group
with a high value of component 2 (represented in the y-
axis on Figure 7(b)). The fusion negative aRMS constitute a
separate group even if some samples were diﬃcult to classify
in accordance with their uncertain diagnosis. Even if the
number of samples was low for each subset, a statistical
analysis showed a signiﬁcant P value between (Pax3+) and
( P a x 7 + )a n db e t w e e n( P a x + )a n d( P a x −)t u m o u r s ,0 . 0 5a n d
0.0005 respectively (Figure S6).
We showed that miRNA proﬁling was a potent tool to
discriminate fusion negative aRMS from embryonal RMS.
miRNAscouldbeusefulbiomarkerstoimprovethediagnosis
ofthistypeofRMS,sincefusionnegativeaRMSarecurrently
molecularly indistinguishable from eRMS [7].
4. Discussion
miRNA signatures are observed for many types of cancers,
that is, sarcoma [19], breast and prostate cancers [18, 32].
These signatures constitute potent diagnosis and prognosis
tools for chronic lymphocytic leukemia [33], colon ade-
nocarcinoma [34], or lung cancers [35]. Here, we showed
that osteosarcoma cell lines also expressed miRNA patterns
diﬀerent from those of chondrosarcoma and lymphoma
cells (Figure 1(a)) and which allow us to discriminate cell
response to chemotherapeutic treatment (Figures 1(b), 2,
and S3). In addition, osteosarcoma miRNA signatures were
cell and drug speciﬁc (Figure 2(a)). This drug speciﬁcity of
osteosarcoma has also been observed by Song et al. with
U2-OS osteosarcoma tumour xenografts, in which diﬀerent
miRNAs were deregulated in response to the chemothera-
peutic agents doxorubicin, cisplatin, and ifosfamide; only
3 miRNAs were commonly found deregulated in response
to all drugs [36]. With their speciﬁcity, miRNAs constitute
promising biomarkers to anticipate the tumour response to
a treatment of interest. As we have recently shown, through
m i R N Ap r o ﬁ l i n g ,w ew e r ea b l et op r e d i c to s t e o s a r c o m a
tumour response to chemotherapy for rat tumours as well as
for patient FFPE biopsies [25]. Here, we showed that miRNA
proﬁles of osteosarcoma cells were in accordance with their
response to the mTOR inhibitor, RAD-001 (Figures 3 and 4).
The miRNAs deregulated in response to this drug in sensitive
cells,eﬀectivelytargetedthemTORpathway,inparticularthe
downstream proteins eIF4G and p70 S6 kinase (Figure 3(b)),
and potentially RICTOR, ATG1 and HIF1a, which might be
validated by qPCR analysis (Figure 5).
In brief, miRNAs appeared very useful for the iden-
tiﬁcation of new exciting therapeutic approaches through
the targeting of some miRNA protein targets or some
miRNAs involved in tumour development themselves. In
future, we would like to conﬁrm the implication of these
miRNAs in treatment response in vitro through the use
of miRNA mimics or inversely of Locked Nucleic Acid
(LNA) against these miRNAs. As mentioned in this study,
we possess an interesting in vitro osteosarcoma model, on
which we could test the miRNA functionality in the presence
of the diﬀerent drugs used in this work. Following the
validation of miRNA involvement in vitro, we would also
test these mimics or LNAs in vivo in the model of rat
osteosarcoma.Thisapproachhasbeensuccessfullyemployed
in rhabdomyosarcoma through the conditional expression of
miR-206inmice[37]andcouldbecomeapotenttherapeutic
strategies [38].
In addition to the identiﬁcation of new targets, miRNA
also constitute an interesting alternative to the conventionalSarcoma 9
mTOR signalling pathway
Growth factors
Hormones
Extracellular
amino acids
Ras/
MAPK
MAPK signalling
pathway
INS/IGF
ERK1/2
RSK
REDD1
Hypoxia
LKB1
BRAF Differentiation
AMPK
TSC1
TSC2
Rheb
AKT mTOR
mTOR
Raptor
3091
S6K1/2
4EBP1
9706 3409
VEGF
VEGF signalling
pathway
Regulation of
autophagy
elF4B
elF4E
Cell growth Translation
DNA
S6
253260
PDK1
PI3K
Insulin signalling
pathway
STRAD
51719
AMP
Energy
stress
AICAR
Metformin
?
?
Amino acids
LY294002
Wortmannin
Rapamycin
or ifs analogs
GβL
GβL
PIP3
+p
+p
+p
+p
+p
+p
+p +p
+p
+p
+p
+p
+p
+p
Figure 5: The discriminating miRNAs interfered with the mTOR pathway. Proteins in yellow, orange, and red colours represent targets of
miRNAs; a yellow square represents a weak repression, while red represents the maximal repression; green squares were not targeted.
molecular technologies routinely used for cancer diagnosis.
In fact, osteosarcoma present complex karyotypic alterations
rendered them diﬃcult to diagnose with current diagnostic
methods, like CGH array [39]. With the rat osteosarcoma
model,weconﬁrmedthattumourspresentednumerouslong
chromosomal aberrations (Figure 6). These abnormalities
were generally common to all tumours, regardless to their
susceptibility to treatment and neither miRNAs of interest
nor genes were located in these regions (Figure S4). Even
if some proteins involved in the regulation of miRNA
expression (trans-acting factors or epigenetic regulating
factors) could be deregulated following these mutations,
the miRNA proﬁles observed in rat tumours might be
correlated to the eﬀects of the cytotoxic drugs on the miRNA
machinery and no to upstream DNA rearrangements. Even
if miRNAs could be submitted to epigenetic regulation like
methylation or acetylation, this only concerns 5% to 10%
miRNAs, and we could consider that this process is minor
for the miRNA signature of osteosarcoma tumours and
cells based on 61miRNAs [40, 41]. Enthusiastically, our
work is the ﬁrst suggesting that miRNA signatures were
not correlated to DNA ampliﬁcations, as it was observed
for neuroblastoma [42] or in mixed lineage leukemia [43].
Although our cohort was not fully satisfying, it appeared
that miRNA proﬁling could predict tumour response to
treatment by reﬂecting tumour biological speciﬁcities and
not genotypic characteristics. This work also highlights
miRNA measurement as an interesting partner to CGH
array in the case of pathologies with unstable karyotypes.
In the same way, Selvarajah et al. was the ﬁrst to suggest a
combination of CGH array and interphase FISH to better
understanding osteosarcoma pathogenesis [44].
miRNApatternswerenotonlyrelatedwithosteosarcoma
phenotypic properties but also with rhabdomyosarcoma
histological subtypes. By miRNA proﬁling, we were able to
discriminate the diﬀerent subtypes of rhabdomyosarcoma:
Pax3+ or Pax7+ or fusion negative, classically diﬃcult to
diagnose by histological analysis (Figure 7(a)). This miRNA
pattern was unique since all miRNAS identiﬁed as discrim-
inating are no or weakly described in the literature. Very
interestingly, on the basis of their miRNA proﬁles, our
algorithms allow us to discriminate embryonal RMS from
fusionnegativeaRMS(Figure 7(b)).Itwasinagreementwith
the work of Wachtel et al. identifying diﬀerent expression
proﬁles linked to aRMS (Pax+), fusion negative aRMS, and
eRMS [45].
Altogether, it seems that miRNA measurement is advan-
tageous for sarcoma with complex karyotype, since fusion
negative RMS, similarly to osteosarcoma, are characterized
by a complex karyotype linked to allelic imbalance, loss of
heterozygoty and heterogeneous gene expression proﬁles.
AlthoughthemolecularclassiﬁcationoffusionnegativeRMS
is always controversial, our work corroborates the study of
Davicioni et al.suggesting thatPax/FOXO1 dictatesaspeciﬁc10 Sarcoma
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Figure 6: CGH analysis of six tumours from an osteosarcoma rat model. Here, we represent six chromosomes among the twenty + X
chromosomes present in rat genome. All the analyses were performed with the same untreated bone sample as a reference.
expression signature in RMS by oligonucleotide microarray
expression proﬁling [46]. Inversely, this diﬀers from the
recent work of Williamson suggesting that fusion negative
alveolar rhabdomyosarcoma is diﬃcult to distinguish from
embryonal rhabdomyosarcoma concerning patient survival
characteristics, gene expression proﬁles, and CGH arrays [7].
In fact, our work and theirs were not totally contradictory,
since they only focused on genomic analysis. As suggested
for osteosarcoma, miRNA patterns reﬂect the phenotypic
tumour properties rather than its genetic and could beSarcoma 11
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Figure 7: Rhabdomyosarcoma miRNA signatures were consistent
with their molecular alterations. (a) This supervised hierarchical
clustering only conserved miRNA diﬀerently expressed in the
diﬀerent subtypes of RMS following an ANOVA (P<. 03).
Each row represents the relative levels of expression for each
miRNA, and each column shows the expression levels for each
sample. The red or green colour indicates relatively high or low
expression, respectively, while grey squares indicate no expressed
miRNA. (b) Principal component analysis of RMS tumours as
a tool to determine the potential tumour response to treatment.
RQ values of the ten selected miRNAs for each tumour were
corrected by the coeﬃcients determined in (a), as described in
Section 2.6.
a promising alternative for RMS diagnosis to surpass the
current limitations of molecular analysis combined to tradi-
tional histopathology.
Thus, it seems that miRNA proﬁling could be very useful
for osteosarcoma and rhabdomyosarcoma diagnosis. Here,
we showed that on the basis of ten miRNAs, we were able to
separate the diﬀerent subtypes of RMS. We have previously
suggested that a panel of ﬁve miRNAs was statistically
suﬃcient to distinguish the potent response of osteosarcoma
patients to treatment [25]. The TLDA technology presents
numerous advantages including its need for few amount of
total RNA and the possible analysis of FFPE samples, as
it was previously shown by others [47–49]. This method
is especially useful to detect circulating miRNAs in patient
serum, an emerging ﬁeld these two past years [50, 51].
A blood-based molecular diagnosis tool through miRNA
proﬁling from patient serum could be a major advance for
osteosarcoma, requiring a biopsy for its diagnosis, which
could result in a secondary amputation.
Altogether, these promising results open up the way to
a new diagnosis tool based on miRNA for osteosarcoma as
well as rhabdomyosarcoma, which could improve patient
survival in both cases through the prediction of patient
response to chemotherapy and the precise identiﬁcation of
RMS subtypes, respectively.
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